4.6 Review

Oncolytic viruses as experimental treatments for malignant gliomas: Using a scourge to treat a devil

Journal

CYTOKINE & GROWTH FACTOR REVIEWS
Volume 21, Issue 2-3, Pages 103-117

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2010.04.001

Keywords

Glioma; Oncolytic virus; Clinical trials; Neuroimmunology; Neurovirulence; Viral delivery; Brain tumor-initiating cells; Synergizing treatments

Ask authors/readers for more resources

The concept of oncolytic viral therapy has a century-old history, but only within the last 20 years have oncolytic viruses been considered for the treatment of brain cancers. Viruses such as herpes, measles, and vaccinia have all been known to cause devastating cases of neurological disease in humans, yet these 'scourges' are now being harnessed in such a way that they prove very useful as cancer therapeutics. There have been 8 formal clinical trials and 3 case studies using oncolytic viruses to treat malignant glioma patients. Although some success has been reached with oncolytic therapy, overall it has fallen short of expectations. In this review we analyze the results of these trials and bring to light some of the limitations and pitfalls of this therapy, as well as present some promising preclinical work that has been proposed to circumvent such problems. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available